



## **RaQualia Receives a Lump-Sum Payment from Hisamitsu Pharmaceutical**

Nagoya, Japan, October 30, 2024 – RaQualia Pharma Inc. (headquartered in Nagoya, Japan; President & CEO: Hirobumi Takeuchi, “RaQualia”) was informed from Hisamitsu Pharmaceutical Co., Inc. (“Hisamitsu Pharmaceutical”) that Hisamitsu Pharmaceutical has reached a development milestone with a transdermal patch containing a novel sodium channel blocker, RQ-00350215, which RaQualia licensed to Hisamitsu Pharmaceutical.

RQ-00350215 blocks the function of specific sodium channels involved in the transmission of pain signals. Hisamitsu Pharmaceutical is currently conducting clinical development using the transdermal patch containing the compound.

In December 2021, Hisamitsu Pharmaceutical and RaQualia entered into a license agreement concerning novel sodium channel blockers. Under the terms of the agreement, RaQualia grants Hisamitsu Pharmaceutical the exclusive worldwide rights to develop, manufacture, and commercialize novel sodium channel blockers, including RQ-00350215. RaQualia is entitled to receive milestone payments based on the development progress and sales royalties, as well as sales milestone payments based on product sales after the product launch. As a result of the milestone achievement, RaQualia will receive a lump-sum payment of 100 million yen from Hisamitsu Pharmaceutical for the achievement of the development milestone, which will be recorded as business income for the fourth quarter of the fiscal year ending December 31, 2024. RaQualia will not revise its consolidated earnings forecast for the current fiscal year ending December 31, 2024, which was announced on February 14, 2024, at this time, but will promptly announce any necessary revisions to the forecast as soon as they are determined.

RaQualia will continue to collaborate with Hisamitsu Pharmaceutical to further improve the quality of life of patients suffering from pain by providing them with new options for pain treatment, thereby enhancing our corporate value proposition.

###

**RaQualia Pharma, Inc. Media Contact:**

RaQualia Pharma, Inc.

8F Meieki Southside Square, 1-21-19 Meieki Minami Nakamura-ku, Nagoya 450-0003, Japan

Tel: +81-446-6100

Email: [ask@raqualia.com](mailto:ask@raqualia.com)